Recent developments highlight Nyxoah's Q4 2025 earnings results, commercial expansion, and financing activities.

• Nyxoah held its Q4 2025 earnings call and reported a net loss, missing revenue estimates for the quarter [N1][N2].
• The company expanded commercial operations with the launch of the Genio system in the Netherlands in December 2025 [N8].
• Nyxoah secured a favorable CMS reimbursement ruling for the Genio system, supporting US market access [N8].
• Convertible notes issuance in late 2025 raised approximately €41.4 million to support working capital and corporate purposes [S2].
• Nyxoah shares surged in early 2026 following strong preliminary Q4 revenue reports [N6].

Nyxoah has demonstrated progress in commercializing its Genio system, including a launch in the Netherlands and favorable reimbursement decisions, which enhance market access. The company’s ability to raise capital through convertible notes provides financial resources to support growth initiatives. Strong preliminary revenue reports and positive market reactions indicate potential for commercial traction. Experienced management and board members with deep industry knowledge support execution capabilities.

Nyxoah reported significant net losses in 2025, reflecting ongoing investment and commercialization costs. The company operates in a competitive medical device market with risks related to clinical adoption, reimbursement, and regulatory changes. Convertible notes increase financial obligations and may dilute shareholders if converted. Market penetration outside initial launch geographies remains limited, and sustained profitability is not yet demonstrated.

Nyxoah's moat is anchored in its proprietary Genio system technology for OSA treatment, supported by regulatory approvals and reimbursement coverage such as the CMS ruling in the US. The company’s leadership team and board bring significant industry experience, which supports commercialization and clinical adoption efforts. However, the medical device market for OSA is competitive, and Nyxoah's moat depends on continued clinical validation, reimbursement success, and market penetration.

• Financial Losses and Capital Requirements: Nyxoah reported a net loss of €90.085 million for 2025 and relies on capital raises such as convertible notes to fund operations, indicating ongoing cash burn and financing risk.
• Market Adoption and Competition: The medical device market for OSA treatment is competitive, and Nyxoah faces risks in achieving broad clinical adoption and reimbursement coverage beyond initial markets.
• Convertible Notes Obligations: The issuance of amortizing convertible notes with interest and potential share conversion creates financial obligations and dilution risk for shareholders.
• Regulatory and Reimbursement Risks: While Nyxoah has secured favorable CMS reimbursement, changes in regulatory or reimbursement policies could impact market access and revenue potential.

• Nyxoah SA is a medical technology company headquartered in Belgium focused on developing and commercializing the Genio system for obstructive sleep apnea (OSA) treatment [S1][N8].
• The company has a senior management team including CEO Olivier Taelman, CFO John Landry, CTO Bruno Onkelinx, and Chief Commercial Officer Scott Holstine [S1].
• Nyxoah's board includes experienced non-executive directors with backgrounds in life sciences and medical devices [S1].
• The company launched the Genio system commercially in the Netherlands in December 2025 [N8].
• Nyxoah received a favorable CMS reimbursement ruling for the Genio system, supporting market access in the US [N8].
• The company reported a net loss of €90.085 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -2.364 EUR/shares [S1].
• As of December 31, 2025, Nyxoah held €30.001 million in cash and equivalents and had current assets of €61.213 million against current liabilities of €48.958 million, resulting in a current ratio of 1.25 and a cash ratio of 1.32 [S1].
• Nyxoah issued senior amortizing unsecured convertible notes totaling approximately €41.4 million in late 2025, with proceeds intended for working capital and corporate purposes [S2].
• The company’s convertible notes bear interest at 6.5% per annum and amortize in quarterly installments over three years, with options for payment in cash or shares [S2].
• Nyxoah’s recent quarterly earnings calls and reports indicate ongoing commercial expansion and clinical data gathering efforts [N1][N2].
• The company’s shares experienced a surge in early 2026 following strong preliminary Q4 revenue reports [N6].